Dec 17 (Reuters) - Actuate Therapeutics Inc :
* ACTUATE THERAPEUTICS ANNOUNCES POSITIVE INTERIM PHASE 2 DATA OF ELRAGLUSIB IN FIRST LINE TREATMENT OF METASTATIC PANCREATIC CANCER
* ACTUATE THERAPEUTICS INC - ELRAGLUSIB IN COMBINATION WITH GNP SHOWS FAVORABLE RISK-BENEFIT PROFILE
* ACTUATE THERAPEUTICS INC - TRIAL MET PRIMARY SAFETY ENDPOINT, FAVORABLE RISK-BENEFIT PROFILE
Source text: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.